Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Assets (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Current Assets data on record, last reported at $639.5 million in Q3 2025.

  • For Q3 2025, Current Assets rose 17.13% year-over-year to $639.5 million; the TTM value through Sep 2025 reached $639.5 million, up 17.13%, while the annual FY2024 figure was $534.1 million, 9.08% up from the prior year.
  • Current Assets reached $639.5 million in Q3 2025 per AMPH's latest filing, up from $580.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $639.5 million in Q3 2025 and bottomed at $300.2 million in Q1 2021.
  • Average Current Assets over 5 years is $446.7 million, with a median of $407.7 million recorded in 2023.
  • Peak YoY movement for Current Assets: skyrocketed 41.33% in 2023, then increased 0.54% in 2024.
  • A 5-year view of Current Assets shows it stood at $318.1 million in 2021, then grew by 18.92% to $378.3 million in 2022, then rose by 29.41% to $489.6 million in 2023, then grew by 9.08% to $534.1 million in 2024, then rose by 19.74% to $639.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $639.5 million in Q3 2025, $580.8 million in Q2 2025, and $588.0 million in Q1 2025.